New drug combo targets ALS inflammation in genetically selected patients
NCT ID NCT07321860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs (galunisertib and nerandomilast) can slow the progression of ALS in 60 people who have high levels of a protein called GREM2. The drugs aim to reduce brain inflammation and nerve cell damage. Participants will receive either the drug combination or a placebo for 24 weeks, and researchers will measure changes in biomarkers related to inflammation and nerve injury.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain implant aims to give voice to those trapped in silence
- Nasal spray aims to tame brain inflammation in ALS
- Robotic arm could help people with paralysis regain independence at home
- Experimental cell therapy tested in 3 ALS patients
- Gene therapy injection hopes to slow ALS
- Super-Sharp brain scanner could revolutionize diagnosis of dementia and cancer